Connect with us


Best Penny Stocks To Buy? 4 That Redditors Are Watching Now

Penny stocks to buy according to Reddit sentiment.
The post Best Penny Stocks To Buy? 4 That Redditors Are Watching Now appeared first on Penny Stocks…



Penny Stocks To Buy According to Redditors

This article looks at penny stocks to buy according to Reddit sentiment. While the social discussion is far from deep-dive due diligence, Main Street traders have established a commanding voice that can’t go unnoticed. Whether you’re talking about the next round of multi-bagger penny stocks or which rumors are driving momentum, chances are that social media will reveal what retail traders are watching and why.

Thanks to the boom (and bust) of stocks like AMC Entertainment (NYSE: AMC) and GameStop (NYSE: GME) during the pandemic, thousands of new traders are finding opportunities in the stock market. Today, that opportunity has been found in cheap stocks, and the last few weeks have shown this first-hand. Bed Bath & Beyond (NASDAQ: BBBY), Blue Apron (NYSE: APRN), and Altimmune (NASDAQ: ALT) are just a few examples of how significant of a move penny stocks can make. The retail community used social media to communicate sentiment and trade scenarios in all three examples.

Penny Stocks To Buy [or avoid]

Weighing your risk and reward is crucial, especially if social sentiment is part of your research process. Believe it or not (insert sarcasm), everything discussed on social media isn’t as accurate as some assume. And (gasp), in many instances, some use social platforms to tout misinformation to ignite bullish interest in companies. With today’s list of penny stocks, keep this in mind, and it’s not a bad idea to do further research beyond social sentiment.

Today we look into some recent catalysts that have contributed to market momentum. We also look into what potential events could be coming down the road. Once you’ve got the essential info, you can decide if they deserve a place on your list of penny stocks to buy or if you should avoid them entirely.

[READ MORE] Hot Penny Stocks To Buy For Under $1 Right Now

Mobilicom Ltd. (MOB)

What To Watch With MOB Stock

A recent IPO IS Mobilicom Ltd. Shares were priced at $4.13 in this month’s public debut, managed to reach a high of $6.66, and promptly fell 65% in the days to follow. Now, only five days after being a public company, shares of MOB stock seem to have gained a more bullish appeal than bearish. Wednesday saw the penny stock jump over 30%, with the highest single-day volume in the company’s public history.

There weren’t any headlines to pair with the move, but it was worth noting that August 30th was the closing date of the public offering. Moreover, the company provides cybersecurity and smart solutions for numerous technology platforms. These include drones and autonomous applications.

Thanks to the attention that some cyber names have received in light of more robust earnings performance, related stocks have gotten a boost at the end of August.

Applied DNA Sciences Inc. (APDN)

What To Watch With APDN Stock

A few things going on with Applied DNA have the market paying attention. First, the 13% short interest (according to Fintel.IO and TDAmeritrade) places it on the list of short squeeze stocks to watch. Meanwhile, the surge in trading this month has done its part in turning heads toward the biotech company.

We discussed APDN stock in our article Best Penny Stocks To Buy Now? 4 Monkeypox Stocks To Watch This Week. In particular, we talked about how it announced the start of analytical validation of a PCR-based monkeypox virus test. Applied DNA has submitted a package to the New York State Department of Health for approval.

As the market awaits a response, speculation has grown. The first confirmed death of a monkeypox patient in Texas has brought a much brighter spotlight to some of the top monkeypox stocks this week. Paired with attention on short squeeze stocks, APDN has found itself in social discussions before September kicks off.

penny stocks to buy Applied DNA APDN stock chart

Graphex Group Ltd. (GRFX)

What To Watch With GRFX Stock

New IPO stocks are something that retail traders can’t seem to get enough of. Albeit many of these implode entirely following the first day of trading (like MOB stock), it hasn’t deterred traders from trying to catch lightning in a bottle. Graphex recently priced its upsized public offering of 4,695,653 at $2.50; besides a few brief moments, GRFX stock hasn’t budged much from this price range.

The company is a graphite processor, and thanks to attention on EV stocks, it has gained some attention recently. This week has seen a more bullish reaction thanks to a new update on Wednesday. Graphex announced interim financial highlights and expansion progress for the year’s first six months.

“We expect continued stability in the second half of 2022 and look forward to moving ahead with our expansion plans for the graphene business in Asia and the U.S.,” said Andross Chan, CEO of Graphex Group. “Growth in the EV market in Asia continues to accelerate, and we believe we have positioned our graphene products very well to participate in that growth.”

Graphex discussed increasing production of graphite from 10,000 to 40,000 tons per year to meet growing demand. It also said that active negotiations are taking place while pursuing new material sources in the US, Brazil, Canada, Africa, Australia, and Europe.

Against the backdrop of a robust EV market, raw materials providers have gained some appeal among retail traders, and for some, GRFX stock is one of the names on the watch list right now.

penny stocks to buy Graphex Group Ltd. GRFX stock chart

Burning Rock Biotech Ltd. (BNR)

What To Watch With BNR Stock

Though it’s late in the season, earnings are still flowing in the stock market. Burning Rock Biotech is one of the latest to report. The precision oncology company released Q2 results this week and gave a business update. Despite missing on revenue estimates, it was the 2022 outlook that seems to have caught the interest of traders in the stock market today.

[READ MORE] Top Penny Stocks To Watch Before September 2022

Burning Rock explained that its retaining full year 2022 revenue guidance of roughly RMB620 million (US$92.6 million) “for now,” and would “like to highlight the risks of further Covid-related impact in the second half of 2022, which is beyond the Company’s control and inherently difficult to forecast.”

Against this backdrop, it seems that the market took this as a bigger positive in the face of worse revenue performance.

penny stocks to buy Burning Rock Biotech Ltd. BNR stock chart

List Of Penny Stocks In This Article

  1. Mobilicom Ltd. (NASDAQ: MOB)
  2. Applied DNA Sciences Inc. (NASDAQ: APDN)
  3. Graphex Group Ltd. (NYSEAMERICAN: GRFX)
  4. Burning Rock Biotech Ltd. (NASDAQ: BNR)

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Best Penny Stocks To Buy? 4 That Redditors Are Watching Now appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Revive Therapeutics To Re-Apply For Primary Endpoint Change With The FDA

Today, Revive Therapeutics Ltd. (CNSX: RVV) (OTCMKTS: RVVTF) provided an update to investors pertaining to its current Phase 3 clinical trial to evaluate…



Today, Revive Therapeutics Ltd. (CNSX: RVV) (OTCMKTS: RVVTF) provided an update to investors pertaining to its current Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19. If the desired outcome is successful, it could remediate last week’s FDA decision and set the trial on a positive trajectory once again.

Following the company’s recent submission of amended protocol to the FDA—in which endpoints related to time to resolution using the polymerase chain reaction (PCR) test was not accepted—Revive Therapeutics has charted a different path.

It now will submit a revised primary efficacy protocol assessing the difference between participants with at least two clinical improvements in symptoms of COVID-19 at Day 14, compared with baseline between Bucillamine versus placebo. Time to resolution via PCR test now becomes a secondary endpoint—among others—instead of the primary. Ultimately, Revive gets another shot at approval through better refinement and optimization of new endpoint protocols.

Endpoint change sought be Revive Therapeutics to a symptoms focus from hospitalization/death remains in play

Should the FDA agree with the revised protocol, the company’s Data Safety Monitoring Board (DSMB) will review the post-dose data compilation of approximately 500 subjects in the context of the new primary endpoint. From there, the committee shall offer one of several possible courses of action:

• Make a recommendation on continuing the study by enrolling additional patients

• Advise on halting the study early due to positive efficacy showing statistical significance

• Recommend halting the trial due to lack of safety and/or efficacy

Revive expects to submit the revised protocol sometime next week.

In response to today’s news, shares of Revive Therapeutics partially reversed the big-volume downside move experienced on September 28. RVV rallied +47.62% to $0.31 per share on the Canadian Stock Exchange, as traders bought the recent discount given that FDA endpoint approval is still very much in-play.

TDR will have further coverage as warranted.

The post Revive Therapeutics To Re-Apply For Primary Endpoint Change With The FDA appeared first on The Dales Report.

Read More

Continue Reading


Hundreds Of Thousands Of Americans Sought Medical Care After COVID-19 Vaccination: CDC Data

Hundreds Of Thousands Of Americans Sought Medical Care After COVID-19 Vaccination: CDC Data

Authored by Zachary Stieber via The Epoch Times…



Hundreds Of Thousands Of Americans Sought Medical Care After COVID-19 Vaccination: CDC Data

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Hundreds of thousands of Americans sought medical care after getting a COVID-19 vaccine, according to Centers for Disease Control and Prevention (CDC) data released on Oct. 3.

The Center for Disease Control (CDC) headquarters in Atlanta, Ga., in a file photograph. (Jessica McGowan/Getty Images)

Some 782,900 people reported seeking medical attention, emergency room care, and/or hospitalization following COVID-19 vaccination. Another 2.5 million people reported needing to miss school, work, or other normal activities as a result of a health event after getting a COVID-19 vaccine.

The reports were made to the CDC’s V-safe program, a new vaccine safety monitoring system to which users can report issues through smartphones.

The CDC released the data to the Informed Consent Action Network (ICAN) after being sued over not producing the data when asked by the nonprofit. ICAN posted a dashboard summarizing the data.

It took numerous legal demands, appeals, and two lawsuits, and over a year, but the CDC finally capitulated and agreed to a court order requiring them to do what they should have done from day one, release the V-safe data to the public,” Aaron Siri, a lawyer representing ICAN in the case, told The Epoch Times in an email.

About 10 million people utilized V-safe during the period of time the data covers: Dec. 14, 2020, to July 31, 2022. About 231 million Americans received at least one vaccine doses during that time.

The V-safe users reported about 71 million symptoms.

The most commonly reported symptoms were chills (3.5 million), swelling (3.6 million), joint pain (4 million), muscle or body aches (7.8 million), headache (9.7 million), fatigue (12.7 million), and general pain (19.5 million).

About 4.2 million of the symptoms were of severe severity.

Users of V-safe filled in data for about 13,000 infants younger than two, reporting over 33,000 symptoms, including pain, loss of appetite, and irritability.

The data produced so far by the CDC does not include free-text responses, according to ICAN. The data covered fields where users checked boxes.

ICAN, founded by film producer Del Bigtree, said that the newly revealed data “reveals shocking information that should have caused the CDC to immediately shut down its COVID-19 vaccine program,” citing the percentage of people who reported needing to get care or missing school, work, or other normal activities, as well as the reported adverse events.

Read more here...

Tyler Durden Thu, 10/06/2022 - 18:20

Read More

Continue Reading


Washington Gave $28M To Chinese Entities For Joint Research Since 2015: Report

Washington Gave $28M To Chinese Entities For Joint Research Since 2015: Report

Authored by Rita Li via The Epoch Times (emphasis ours),




Washington Gave $28M To Chinese Entities For Joint Research Since 2015: Report

Authored by Rita Li via The Epoch Times (emphasis ours),

Recently released findings show U.S. government agencies sent over $28 million in taxpayers’ dollars “directly to Chinese entities” for joint research over a five-year period ending 2021.

A technician works at a DNA tech lab in Beijing on Aug. 22, 2018. (Greg Baker/AFP/Getty Images)

From fiscal years 2015 through 2021, “the CDC [Centers for Disease Control and Prevention], NIH [National Institutes of Health], and DOD [Department of Defense] provided 22 awards totaling $28.9 million directly to Chinese entities including universities and other research institutions,” the Government Accountability Office (GAO) said on Sept. 29 following a trove of analyses.

Researchers found the federal funding focused on “multiple scientific disciplines,” aiding Chinese entities in conducting research on “disease surveillance, vaccination studies, and the development of new drugs,” as well as “alternative technologies to propel vehicles such as drones.”

The release of its 38-page report (pdf) follows a January request from House Republican Conference Chairwoman Elise Stefanik (R-N.Y.) and Michael McCaul (R-Texas), the top Republican on the House Foreign Affairs Committee. They asked GAO to review federal funds provided to China or entities controlled by the Chinese Communist Party (CCP) for collaborative research, and U.S. contributions to multilateral institutions.

Stefanik described such funding as “troubling.”

“China’s deception and stonewalling of the truth behind the origins of COVID-19 has led to millions of senseless deaths and trillions of dollars in economic destruction across the globe,” the congresswoman said in a statement to The Epoch Times.

The three agencies awarded a total of 13 Chinese entities for joint publications, information sharing, and workshops, while 84 percent of the direct funding went to the University of Hong Kong, Peking University, and the Chinese Center for Disease Control and Prevention, known as the Chinese CDC.

Receiving almost $5 million from the NIH and the CDC over the past years, the Chinese CDC had been suppressing information about the outbreak domestically and snubbed U.S. offers of assistance, despite how any health data would have been crucial to formulate a more effective COVID-19 containment strategy and minimize the disease’s global spread.

Health workers wearing personal protective equipment walk on a street in a neighborhood during a COVID-19 lockdown in the Jing’an district in Shanghai on April 8, 2022. (Hector Retamal/AFP via Getty Images)

“Even more frightening,” Stefanik continued, “we still have no idea how much total money has been sent to China due to lax reporting requirements. Make no mistake, the Chinese Communist Party’s deception throughout the pandemic confirmed that China is not a reliable partner.”

Read more here...

Tyler Durden Thu, 10/06/2022 - 17:40

Read More

Continue Reading